These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 4930184)
21. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise]. Ekimoto H Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236 [TBL] [Abstract][Full Text] [Related]
22. How to anticipate the assessment of the public health benefit of new medicines? Massol J; Puech A; Boissel JP; Therapie; 2007; 62(5):427-35. PubMed ID: 18206104 [TBL] [Abstract][Full Text] [Related]
23. Problems of new drugs. Tornya PT Med J Aust; 1970 Jun; 1(25):1266. PubMed ID: 4918052 [No Abstract] [Full Text] [Related]
24. [Therapeutic evaluation of drugs]. Cantor DS Acta Gastroenterol Latinoam; 1971; 3(2):91-2. PubMed ID: 4944345 [No Abstract] [Full Text] [Related]
25. [The elderly healthy volunteer: a necessity]. Allain H; Le Coz F; Bureau M Therapie; 1993; 48(3):239-42. PubMed ID: 8140563 [TBL] [Abstract][Full Text] [Related]
26. [How effective are drugs?--controlled drug trials are needed]. Pentikäinen PJ Duodecim; 1998; 114(10):945, 947, 949. PubMed ID: 11524782 [No Abstract] [Full Text] [Related]
27. [Are children getting the right drugs?]. Bratlid D Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3290-2. PubMed ID: 16327857 [TBL] [Abstract][Full Text] [Related]
28. A phased approach to clinical testing: criteria for progressing from Phase I to Phase II to Phase III studies. André FE; Foulkes MA Dev Biol Stand; 1998; 95():57-60. PubMed ID: 9855414 [TBL] [Abstract][Full Text] [Related]
29. [Controlled drug trials from the forensic view point. Admissibility criteria of the drug law]. Eser A Internist (Berl); 1982 Apr; 23(4):218-26. PubMed ID: 7045024 [No Abstract] [Full Text] [Related]
30. Assessing pharmacokinetic and pharmacodynamic interactions in clinical trials of antiepileptic drugs. Reife RA Adv Neurol; 1998; 76():95-103. PubMed ID: 9408466 [TBL] [Abstract][Full Text] [Related]
31. A cost-related approach for evaluating drug development programs. Yan EC; Chen L Stat Med; 2004 Sep; 23(18):2863-73. PubMed ID: 15344191 [TBL] [Abstract][Full Text] [Related]
32. [Clinical trials with drugs: the influence of the authorization process]. Carcas AJ; Serrano MA; Avendaño C; Galende I; Tristán C; García-Alonso F Med Clin (Barc); 1995 May; 104(18):683-8. PubMed ID: 7769877 [TBL] [Abstract][Full Text] [Related]
33. [Controlled clinical studies of tolerance development and dosing problems in nitrate therapy]. Abshagen U Herz; 1996 Jun; 21 Suppl 1():23-30. PubMed ID: 8767921 [TBL] [Abstract][Full Text] [Related]
34. The use of prior information in the testing of new drugs. Allen DM Biometrics; 1971 Sep; 27(3):699-708. PubMed ID: 4940382 [No Abstract] [Full Text] [Related]
35. New drugs: watch out for unexpected adverse effects. Prescrire Int; 2002 Oct; 11(61):150-1. PubMed ID: 12378747 [TBL] [Abstract][Full Text] [Related]
36. Advances in pediatric pharmacology, therapeutics, and toxicology. Berlin CM Adv Pediatr; 2001; 48():439-64. PubMed ID: 11480767 [TBL] [Abstract][Full Text] [Related]
37. Safe and effective drug therapy in older adults. Hume AL Med Health R I; 2005 Jan; 88(1):15-7. PubMed ID: 15779550 [TBL] [Abstract][Full Text] [Related]
38. [Placebo effect in research related to surgery and technical procedures]. Tjomsland O; Ekeberg Ø; Saatvedt K Tidsskr Nor Laegeforen; 2001 Aug; 121(19):2290-3. PubMed ID: 11571882 [TBL] [Abstract][Full Text] [Related]
39. [The guideline for clinical trials proposed by Japan Society for Cancer Therapy (JSCT)]. Kurihara M Gan To Kagaku Ryoho; 1996 Jan; 23(2):156-65. PubMed ID: 8611043 [TBL] [Abstract][Full Text] [Related]
40. New drugs: how to decide which ones to prescribe. Mohler PJ Fam Pract Manag; 2006 Jun; 13(6):33-5. PubMed ID: 16813119 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]